Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. APYX
APYX logo

APYX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.200
Open
4.130
VWAP
4.08
Vol
100.02K
Mkt Cap
171.26M
Low
3.950
Amount
408.07K
EV/EBITDA(TTM)
--
Total Shares
41.87M
EV
177.17M
EV/OCF(TTM)
--
P/S(TTM)
3.09
Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.
Show More

Events Timeline

(ET)
2026-05-07
07:20:00
Company Confirms FY26 Operating Expenses Below $45M
select
2026-05-07
07:20:00
Company Reports Q1 Revenue of $12.49M, Exceeding Expectations
select
2026-03-10 (ET)
2026-03-10
07:10:00
Company Expects Total Revenue of $57.5M to $58.5M for 2026
select
2026-03-10
07:10:00
AYON Reports Q4 Revenue of $19.16M Exceeding Expectations
select
2026-01-12 (ET)
2026-01-12
08:10:00
Apyx Medical's AYON Launch Drives Approx. 51% Revenue Growth in U.S.
select
2025-12-03 (ET)
2025-12-03
08:20:00
Apyx Medical Launches Apyx One Console in South Korea
select
2025-12-01 (ET)
2025-12-01
16:10:00
Apyx Medical Files $100M Mixed Securities Shelf
select

News

Newsfilter
8.5
15:41 PMNewsfilter
PinnedApyx Medical Showcases New Technology at Miami Swim Week
  • Technology Innovation Showcase: Apyx Medical will present its next-generation body contouring system, AYON, at Miami Swim Week, integrating Renuvion and various advanced fat removal technologies to enhance surgeons' treatment flexibility and workflow efficiency, thereby addressing the growing demand for body contouring.
  • Real Patient Transformations: The event will feature real Renuvion patients walking the runway, showcasing their confidence and transformations achieved through advanced aesthetic procedures, emphasizing the company's commitment to reshaping beauty standards and delivering authentic results.
  • Market Demand Response: As patients increasingly seek comprehensive solutions and natural outcomes, Apyx Medical's Body by Apyx event reflects its keen insight into market changes, aiming to attract more clients through real transformation stories.
  • Industry Leadership: AYON, as an FDA-cleared innovative system, combines precision and versatility, marking Apyx Medical's leadership in the surgical aesthetics field, and is expected to provide surgeons with higher returns on investment and consistent treatment outcomes.
PRnewswire
5.0
14:56 PMPRnewswire
Apyx Medical Showcases New Technology at Miami Swim Week
  • Product Innovation Showcase: Apyx Medical will present its next-generation body contouring system, AYON, at Miami Swim Week, integrating Renuvion and various advanced fat removal technologies to enhance surgeons' treatment flexibility and workflow efficiency, thereby addressing the growing demand for body contouring.
  • Real Case Presentations: The event will feature real patient transformation stories, showcasing the latest outcomes in body contouring and emphasizing Apyx Medical's contribution to reshaping beauty standards, further enhancing brand recognition and customer trust.
  • Market Demand Response: As patients increasingly seek more comprehensive and natural body contouring solutions, Apyx Medical's Body by Apyx event demonstrates its keen insight into market changes, aiming to attract more clients through authentic transformation stories.
  • Integrated Technology Advantages: The AYON system combines precision, versatility, and innovation, offering real-time adjustments with LIFT technology and Renuvion's tissue contraction capabilities, helping surgeons achieve higher treatment outcomes and return on investment, marking a revolutionary advancement in the body contouring field.
Newsfilter
8.5
05-11Newsfilter
Apyx Medical Receives Expanded Clearance for AYON System
  • FDA Clearance Expansion: Apyx Medical Corporation has received expanded 510(k) clearance from the FDA for its AYON Body Contouring System to include power liposuction, enhancing fat removal efficiency and reducing surgeon effort and operating room time, establishing the system as the gold standard in surgical aesthetics.
  • Commercial Launch Plan: The company plans to initiate a limited commercial launch of the power liposuction function, aiming to work closely with early adopters to refine training and customer experience, thereby laying the groundwork for future commercial scaling and enhancing market competitiveness.
  • Integrated Platform Benefits: The AYON system integrates fat removal, closed-loop contouring, and Renuvion tissue contraction capabilities, enabling surgeons to perform multiple critical body contouring procedures within one system, significantly streamlining workflow and improving procedural efficiency.
  • Innovative Technology Leadership: With features like LIFT Technology for real-time adjustments and enhanced tissue contraction via Renuvion, the AYON system ensures optimal patient outcomes in surgical procedures, further solidifying Apyx Medical's leadership position in the aesthetic surgery market.
seekingalpha
9.5
05-08seekingalpha
Apyx Medical Reports Strong Q1 2026 Earnings with Revenue Growth
  • Significant Revenue Growth: Apyx Medical reported total revenue of $12.5 million in Q1 2026, a 33% increase from $9.4 million in the same period last year, primarily driven by a 36% rise in Surgical Aesthetics product sales, indicating strong market performance.
  • Strong Product Demand: The AYON body contouring system continues to see robust sales in the U.S., contributing to Surgical Aesthetics revenue of $10.7 million, with FDA clearance for power liposuction anticipated this quarter, further expanding market potential.
  • Optimistic Financial Outlook: The company raised its total revenue guidance for 2026 to a range of $59 million to $60 million, up from the previous guidance of $57.5 million to $58.5 million, reflecting confidence in future performance.
  • Effective Cost Control: Despite tariff pressures, Apyx anticipates gross margins of approximately 62% to 63% for the year, with total operating expenses not exceeding $45 million, demonstrating effective cost management strategies.
seekingalpha
9.5
05-07seekingalpha
Apyx Medical Q1 Earnings Exceed Expectations
  • Earnings Highlights: Apyx Medical reported a Q1 GAAP EPS of -$0.05, beating expectations by $0.06, with revenue of $12.5 million reflecting a 32.6% year-over-year increase, surpassing forecasts by $1.73 million, indicating strong market performance.
  • Upward Revision of 2026 Guidance: The company raised its total revenue guidance for 2026 to a range of $59.0 million to $60.0 million, up from the previous $57.5 million to $58.5 million, reflecting confidence in future growth prospects.
  • Segment Revenue Expectations: Surgical Aesthetics revenue is projected between $54.0 million and $55.0 million, an increase from the prior guidance of $53.0 million to $54.0 million, while OEM revenue is expected to be approximately $5.0 million, up from $4.5 million, showcasing robust growth across business lines.
  • Cost Control Measures: The company anticipates operating expenses to remain below $45.0 million for 2026, ensuring that it maintains cost control while driving revenue growth, thereby enhancing overall profitability and financial health.
PRnewswire
5.0
04-01PRnewswire
Renuvion Wins Best Minimally Invasive Skin Tightener Award Again
  • Award Recognition: Renuvion has been named the 'Best Minimally Invasive Skin Tightener' for the second consecutive year, reflecting its leadership in surgical aesthetics and enhancing trust among physicians and patients, thereby boosting brand recognition in the market.
  • Technological Edge: As the only FDA-cleared device for use after liposuction, Renuvion, combined with the AYON platform, improves physician workflow efficiency and treatment customization, further expanding the company's market share in body contouring.
  • Industry Trust: A 2024 Wakefield Research survey indicates that 80% of surgeons consider Renuvion the most trusted body contouring technology, a statistic that not only enhances product competitiveness but also lays a foundation for future sales growth.
  • Innovation Commitment: Apyx Medical is dedicated to improving patients' lives through its Helium Plasma Platform Technology, with over 90 clinical publications supporting the effectiveness of Renuvion and J-Plasma, further solidifying its leadership position in the cosmetic surgery market.
Wall Street analysts forecast APYX stock price to rise
2 Analyst Rating
Wall Street analysts forecast APYX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
6.00
Averages
7.00
High
8.00
Current: 0.000
sliders
Low
6.00
Averages
7.00
High
8.00
Craig-Hallum
Buy
maintain
$5 -> $6
AI Analysis
2026-03-11
Reason
Craig-Hallum
Price Target
$5 -> $6
AI Analysis
2026-03-11
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Apyx Medical to $6 from $5 and keeps a Buy rating on the shares. The firm notes the company reported a strong quarter with in-line sales and a beat on the bottom line. 2026 guidance exceeded the Street's expectations and yet does not incorporate potential contribution from the liposuction handpiece approval which is expected mid-year. Lastly, expansion geographically via new country approvals and more affordable GLP-1s represent additional opportunities for the company to accelerate growth, Craig-Hallum adds.
BTIG
Sam Eiber
Neutral -> Buy
upgrade
$6
2026-03-11
Reason
BTIG
Sam Eiber
Price Target
$6
2026-03-11
upgrade
Neutral -> Buy
Reason
BTIG analyst Sam Eiber upgraded Apyx Medical to Buy from Neutral with a $6 price target. The firm cites positive early momentum with the Ayon launch, growing demand for skin tightening among consumers taking GLP-1s, and Apyx Medical's expansion opportunities outside the U.S. for the upgrade. Accelerating growth and cost controls offer greater visibility into the company's path to sustainable profitability, which had been a previous core concern, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for APYX
Unlock Now

Valuation Metrics

The current forward P/E ratio for Apyx Medical Inc (APYX.O) is 72.46, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess Apyx Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.99
Current PE
72.46
Overvalued PE
20.17
Undervalued PE
-26.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.21
Current EV/EBITDA
-44.49
Overvalued EV/EBITDA
30.39
Undervalued EV/EBITDA
-48.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.00
Current PS
2.63
Overvalued PS
5.47
Undervalued PS
0.53

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Price Prediction for penny stocks
Intellectia · 86 candidates
Price: <= $5.00Volume: >= 1Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Week Price Change Pct: >= $0.00One Day Rise Prob: >= 51One Day Predict Return: >= 0.0%One Week Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 1
Ticker
Name
Market Cap$
top bottom
APYX logo
APYX
Apyx Medical Inc
160.80M
CPHI logo
CPHI
China Pharma Holdings Inc
40.38M
SNT logo
SNT
Senstar Technologies Corp
64.63M
JZXN logo
JZXN
Jiuzi Holdings Inc
47.53M
MBAI logo
MBAI
Check Cap Ltd
14.04M
WHWK logo
WHWK
Whitehawk Therapeutics Inc
243.80M
scan penny stocks big return tomorrow
Intellectia · 4 candidates
Price: $0.50 - $5.00Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceCrossAboveMA5, PriceCrossAboveMA20One Day Rise Prob: >= 70One Day Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
APYX logo
APYX
Apyx Medical Inc
160.80M
CPHI logo
CPHI
China Pharma Holdings Inc
40.38M
FAMI logo
FAMI
Farmmi Inc
20.17M
SNT logo
SNT
Senstar Technologies Corp
64.63M
상대적 볼륨1.5 이상과 갭상승 2%인 종목들 찾아봐
Intellectia · 60 candidates
Region: USRelative Vol: >= 1.50Pre Market Price Change: >= $2.00
Ticker
Name
Market Cap$
top bottom
CELC logo
CELC
Celcuity Inc
6.07B
XRX logo
XRX
Xerox Holdings Corp
353.10M
LWLG logo
LWLG
Lightwave Logic Inc
2.45B
NICE logo
NICE
Nice Ltd
6.71B
CVV logo
CVV
CVD Equipment Corp
55.85M
EBAY logo
EBAY
eBay Inc
46.21B
yea US penny stocks
Intellectia · 16 candidates
Price: $0.10 - $5.00Volume: >= 300,000Rsi Category: moderate, overboughtPrice Change Pct: $0.00 - $15.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Macd: positive, bullish
Ticker
Name
Market Cap$
top bottom
APYX logo
APYX
Apyx Medical Inc
166.48M
CAPT logo
CAPT
Captivision Inc
19.92M
APM logo
APM
Aptorum Group Ltd
9.85M
RNXT logo
RNXT
RenovoRx Inc
40.68M
TRON logo
TRON
TRON Inc
622.85M
CDLX logo
CDLX
Cardlytics Inc
50.19M
best penny stocks to invest in
Intellectia · 17 candidates
Revenue Ttm: >= 10.00MRegion: USPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 0.0%List Exchange: XNYS, XNAS, XASEMonth Price Change Pct: >= $15.00Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
TYGO logo
TYGO
Tigo Energy Inc
216.68M
TRX logo
TRX
TRX Gold Corp
448.36M
SATL logo
SATL
Satellogic Inc
585.75M
BAER logo
BAER
Bridger Aerospace Group Holdings Inc
158.30M
CHRS logo
CHRS
Coherus Oncology Inc
272.43M
GORO logo
GORO
Gold Resource Corp
216.89M
all
Intellectia · 27 candidates
Price: <= $5.00Relative Vol: >= 1.50Beta: HighRiskRsi 14: 30 - 70Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
RIG logo
RIG
Transocean Ltd
5.10B
BAK logo
BAK
Braskem SA
1.31B
GROY logo
GROY
Gold Royalty Corp
1.10B
OPK logo
OPK
OPKO Health Inc
1.06B
SES logo
SES
SES AI Corp
861.57M
EU logo
EU
enCore Energy Corp
610.54M
any other good options to consider
Intellectia · 41 candidates
Market Cap: <= 1000.00MPrice: <= $5.00Analyst Consensus: Moderate Buy, Strong BuyRelative Vol: >= 1.50Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
SES logo
SES
SES AI Corp
861.57M
LAES logo
LAES
Sealsq Corp
830.10M
GAU logo
GAU
Galiano Gold Inc
745.60M
UROY logo
UROY
Uranium Royalty Corp
655.79M
EU logo
EU
enCore Energy Corp
610.54M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
penny stocks to buy tomorrow
Intellectia · 20 candidates
Market Cap: <= 1000.00MPrice: <= $5.00Relative Vol: >= 1.50Earnings Surprise: EpsBeatWeek Price Change Pct: >= $3.00
Ticker
Name
Market Cap$
top bottom
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
INN logo
INN
Summit Hotel Properties Inc
526.61M
ACTG logo
ACTG
Acacia Research Corp
385.84M
AUNA logo
AUNA
Auna SA
364.88M
GLDG logo
GLDG
GoldMining Inc
344.04M
TYGO logo
TYGO
Tigo Energy Inc
243.42M
What stocks will go up 20% next week?
Intellectia · 24 candidates
Short Ratio: LessThan10PctBeta: HighRiskTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
SM logo
SM
SM Energy Co
2.15B
HLMN logo
HLMN
Hillman Solutions Corp
1.96B
CWH logo
CWH
Camping World Holdings Inc
1.47B
XERS logo
XERS
Xeris Biopharma Holdings Inc
1.26B
DAWN logo
DAWN
Day One Biopharmaceuticals Inc
1.24B
GYRE logo
GYRE
Gyre Therapeutics Inc
754.39M
best short term by under 5 dollars stock
Intellectia · 23 candidates
Market Cap: >= 50.00MPrice: <= $5.00Relative Vol: >= 1.50Beta: HighRiskWeek Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
RIG logo
RIG
Transocean Ltd
5.10B
DNN logo
DNN
Denison Mines Corp
3.36B
BAK logo
BAK
Braskem SA
1.31B
GROY logo
GROY
Gold Royalty Corp
1.10B
OPK logo
OPK
OPKO Health Inc
1.06B
SES logo
SES
SES AI Corp
861.57M

Whales Holding APYX

N
Nantahala Capital Management, LLC
Holding
APYX
+9.64%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Apyx Medical Inc (APYX) stock price today?

The current price of APYX is 4.09 USD — it has decreased -0.97

What is Apyx Medical Inc (APYX)'s business?

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.

What is the price predicton of APYX Stock?

Wall Street analysts forecast APYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APYX is7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Apyx Medical Inc (APYX)'s revenue for the last quarter?

Apyx Medical Inc revenue for the last quarter amounts to 12.49M USD, increased 32.45

What is Apyx Medical Inc (APYX)'s earnings per share (EPS) for the last quarter?

Apyx Medical Inc. EPS for the last quarter amounts to -0.05 USD, decreased -50.00

How many employees does Apyx Medical Inc (APYX). have?

Apyx Medical Inc (APYX) has 205 emplpoyees as of May 27 2026.

What is Apyx Medical Inc (APYX) market cap?

Today APYX has the market capitalization of 171.26M USD.